DDInter1763 DDInter1733
Temsirolimus is a derivative of sirolimus used in the treatment of renal cell carcinoma (RCC). It was developed by Wyeth Pharmaceuticals under the trade name Torisel. Temsirolimus was approved by the FDA in late May 2007 as well as the European Medicines Agency (EMEA) on November 2007.
Suvorexant is a selective dual antagonist of orexin receptors OX1R and OX2R that promotes sleep by reducing wakefulness and arousal. It has been approved for the treatment of insomnia.
Temsirolimus {u} (Compound) upregulates {v} (Gene) TESK1
TESK1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) binds {v} (Gene) ABCB1
ABCB1 {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) upregulates {v} (Gene) TESK1
TESK1 {u} (Gene) is downregulated by {v} (Compound) Pazopanib
Pazopanib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) upregulates {v} (Gene) TESK1
TESK1 {u} (Gene) is upregulated by {v} (Compound) Dabrafenib
Dabrafenib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) downregulates {v} (Gene) CSK
CSK {u} (Gene) is bound by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) upregulates {v} (Gene) TESK1
TESK1 {u} (Gene) is bound by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Temsirolimus {u} (Compound) upregulates {v} (Gene) HLA-DRA
HLA-DRA {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Temsirolimus {u} (Compound) downregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is upregulated by {v} (Compound) Dasatinib
Dasatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) downregulates {v} (Gene) LRPAP1
LRPAP1 {u} (Gene) is downregulated by {v} (Compound) Cyproheptadine
Cyproheptadine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Suvorexant
Temsirolimus {u} (Compound) upregulates {v} (Gene) IKBKE
IKBKE {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Crizotinib {u} may lead to a major life threatening interaction when taken with {v} Suvorexant
Temsirolimus (Compound) upregulates TESK1 (Gene) and TESK1 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) upregulates TESK1 (Gene) and TESK1 (Gene) is downregulated by Pazopanib (Compound) and Pazopanib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) upregulates TESK1 (Gene) and TESK1 (Gene) is upregulated by Dabrafenib (Compound) and Dabrafenib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) downregulates CSK (Gene) and CSK (Gene) is bound by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) upregulates TESK1 (Gene) and TESK1 (Gene) is bound by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant
Temsirolimus (Compound) upregulates HLA-DRA (Gene) and HLA-DRA (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant
Temsirolimus (Compound) downregulates LRPAP1 (Gene) and LRPAP1 (Gene) is upregulated by Dasatinib (Compound) and Dasatinib may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) downregulates LRPAP1 (Gene) and LRPAP1 (Gene) is downregulated by Cyproheptadine (Compound) and Cyproheptadine may cause a moderate interaction that could exacerbate diseases when taken with Suvorexant
Temsirolimus (Compound) upregulates IKBKE (Gene) and IKBKE (Gene) is bound by Crizotinib (Compound) and IKBKE (Gene) is upregulated by Crizotinib (Compound) and Crizotinib may lead to a major life threatening interaction when taken with Suvorexant